JP2019504085A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504085A5
JP2019504085A5 JP2018540107A JP2018540107A JP2019504085A5 JP 2019504085 A5 JP2019504085 A5 JP 2019504085A5 JP 2018540107 A JP2018540107 A JP 2018540107A JP 2018540107 A JP2018540107 A JP 2018540107A JP 2019504085 A5 JP2019504085 A5 JP 2019504085A5
Authority
JP
Japan
Prior art keywords
agent
subject
administration
fasting
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540107A
Other languages
English (en)
Japanese (ja)
Other versions
JP7082258B2 (ja
JP2019504085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/014034 external-priority patent/WO2017136143A1/en
Publication of JP2019504085A publication Critical patent/JP2019504085A/ja
Publication of JP2019504085A5 publication Critical patent/JP2019504085A5/ja
Application granted granted Critical
Publication of JP7082258B2 publication Critical patent/JP7082258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540107A 2016-02-01 2017-01-19 うっ血性心不全に罹っている対象を治療するためのリボースの使用 Active JP7082258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289562P 2016-02-01 2016-02-01
US62/289,562 2016-02-01
PCT/US2017/014034 WO2017136143A1 (en) 2016-02-01 2017-01-19 Use of ribose for treatment of subjects having congestive heart failure

Publications (3)

Publication Number Publication Date
JP2019504085A JP2019504085A (ja) 2019-02-14
JP2019504085A5 true JP2019504085A5 (enExample) 2020-02-27
JP7082258B2 JP7082258B2 (ja) 2022-06-08

Family

ID=57915160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540107A Active JP7082258B2 (ja) 2016-02-01 2017-01-19 うっ血性心不全に罹っている対象を治療するためのリボースの使用

Country Status (4)

Country Link
US (1) US10821123B2 (enExample)
EP (2) EP3411041A1 (enExample)
JP (1) JP7082258B2 (enExample)
WO (1) WO2017136143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114209709A (zh) * 2021-12-16 2022-03-22 海门品尚医药科技有限公司 D-核糖在制备改善药物性心脏毒性药物或食品中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605644A (en) 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4719201A (en) 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4824660A (en) 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
AU2228888A (en) 1987-10-14 1989-05-25 Takeda Chemical Industries Ltd. Aqueous pharmaceutical preparation for oral administration
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US4968719A (en) 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
JPH02286620A (ja) 1989-04-27 1990-11-26 Riide Chem Kk 抗高脂血症用剤
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5114723A (en) 1990-02-27 1992-05-19 University Of Texas System Board Of Regents Beverage compositions for human consumption
IT1247125B (it) 1991-03-01 1994-12-12 Depha Team Srl Composizioni dietetiche o farmaceutiche per il ripristino del contenuto cellulare degli adenin nucleotidi nel muscolo scheletrico e cardiaco.
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
DE4228215A1 (de) 1992-08-25 1994-03-03 Pliml Wolfgang Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen
ES2196053T3 (es) 1994-01-11 2003-12-16 Stichting Zofia Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
AU1780395A (en) 1994-05-02 1995-11-09 Omeara (Proprietary) Limited Amino acid, carnitine and magnesium supplementation
US5536751A (en) 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
GB9517443D0 (en) 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
US5707971A (en) 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US5804596A (en) 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
US6054128A (en) 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6429198B1 (en) 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US6534480B2 (en) 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6339716B1 (en) 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6159943A (en) 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6172114B1 (en) 1999-09-30 2001-01-09 Worldwide Sports Nutritional Supplements, Inc. Creatine supplement
US6703370B1 (en) 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
US6663859B2 (en) 2000-01-07 2003-12-16 Bioenergy, Inc. Compositions for enhancing the immune response
US6525027B2 (en) 2000-01-20 2003-02-25 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20030212006A1 (en) 2002-05-13 2003-11-13 Seifert John G. Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals
US20090197818A1 (en) 2004-01-14 2009-08-06 St Cyr John A Use Of Ribose for Recovery From Anaesthesia
US20050277598A1 (en) 2004-04-29 2005-12-15 Maccarter Dean J Method for improving ventilatory efficiency
US20100099630A1 (en) 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US8835396B2 (en) 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
US8101581B2 (en) 2007-01-23 2012-01-24 Bioenergy, Inc. Use of D-ribose to treat cardiac arrhythmias
WO2009094593A1 (en) * 2008-01-25 2009-07-30 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure
WO2009123742A1 (en) 2008-04-02 2009-10-08 St Cyr John A Use of ribose in first response to acute myocardial infarction
US20090286750A1 (en) 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons

Similar Documents

Publication Publication Date Title
Abete et al. Treatment for chronic heart failure in the elderly: current practice and problems
Tsang et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness
JP2020529996A5 (enExample)
Katayama et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy
HRP20220058T1 (hr) Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja
EP2300001A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
Srivatsa et al. Sarcoidosis and atrial fibrillation: a rare association and interlink with inflammation
JP2019504085A5 (enExample)
Ulus et al. Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy
Bisognano et al. Improved functional capacity and cardiovascular structure after baroreflex activation therapy™ in resistant hypertension patients with symptomatic heart failure: Results from European and United States trials of the Rheos® system
Hatala et al. SYMBIO: RESULTS OF A LONGITUDINAL STUDY OF OPTIMIZED BLOOD PRESSURE LOWERING THERAPY WITH FIXED COMBINATION PERINDOPRIL/AMLODIPINE: PP. 5.169
Paraskevaidis et al. Narrow QRS complex in idiopathic (fascicular) left ventricular tachycardia
JP7082258B2 (ja) うっ血性心不全に罹っている対象を治療するためのリボースの使用
Hamabe et al. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing–induced model of heart failure
Hayashi et al. A case of adriamycin-induced cardiomyopathy implanted artificial heart after having the uncontrollable arrhythmia
Psychari et al. DDDR pacing results in left ventricular asynchrony with preservation of ejection fraction and NT-proBNP: A prospective study in sick sinus syndrome and normal ventricular function
Latoguz Treatment Features of Ciliary Arrhythmia in Patients with Ischemic Heart Disease in Combination with Diabetes Innocens
Dufourni et al. Left ventricular function during atrial fibrillation and follow up after succesfull cardioversion to sinus rhythm in warmblood horses
de Freitas Ribeiro et al. Pulmonary hypertension in a patient with hyperthyroidism
Efanov et al. ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397
RU2012143550A (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для введения вскоре после прекращения введения амиодарона
Zile et al. A phase 2 randomized, double-blind, placebo-controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure
Mizuno et al. NPPV Improves Respiratory Acidosis of Kounis Syndrome
Grospietsch Risk of drug therapy in cardiac diseases in pregnancy
Naydenov et al. PP. 21.07: PILOT DATA FROM A BULGARIAN STUDY WITH A TRIPLE SINGLE-PILL COMBINATION OF PERINDOPRIL/INDAPAMIDE/AMLODIPINE IN PATIENTS WITH DIFFICULT-TO-CONTROL ARTERIAL HYPERTENSION